MBX to advance hypoparathyroidism drug to Phase III trial
MBX Biosciences is advancing its hypoparathyroidism drug after 63% of patients achieved the primary endpoint of a Phase II trial.…
Hormonal Disorders
-
-
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders
Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth…
-
HopeMed advances its androgenetic alopecia treatment to Phase II trials
Hope Medicine has kickstarted recruitment for a Phase II trial assessing its monoclonal antibody HMI-115 for androgenetic alopecia, after the…
-
Genexine’s GX-H9 therapy trial meets primary endpoint
Genexine has reported that the Phase III study of eftansomatropin alfa (GX-H9) for the treatment of children with growth hormone…
-
Xeris Biopharma dosing patients in hypothyroidism drug trial
US-based pharmaceutical company Xeris Biopharma has dosed the first participant in a Phase II clinical trial of subcutaneous (SC) XP-8121…
-
Extend Biosciences reports positive data from hypoparathyroidism trial
Extend Biosciences has reported positive results from its first-in-human Phase I clinical trial of EXT608 for the treatment of hypoparathyroidism,…
-
Pipeline Moves: Novartis completes ulcerative colitis trial, advancement prospects rise
This week on Pipeline Moves, we start with the completion of Novartis’s Phase II trial in ulcerative colitis. We also…
-
DCT Adoption Tracker reveals top therapy areas using a decentralisation approach
Telemedicine remains the leading decentralisation approach in clinical trials in Q2 of this year. The continued rise of telemedicine as…
-
Pipeline Moves: Phase I/II cystic fibrosis trial of Horizon asset cancelled, shot at further study drops
In this edition of Pipeline Moves, the Clinical Trials Arena team kicks off with an analysis of the termination of…
-
OPKO Health and Pfizer report positive Phase III data for somatrogon
OPKO Health and Pfizer have reported positive results from the Phase III clinical trial of somatrogon compared to Genotropin (somatropin)…
